

H ng K ng E change, and Clea ing Limi ed and The S ck E change f H ng K ng Limi ed
ake n e n, ibili f he c n en, f hi, ann ncemen, make n e, en a i n a,
i, acc ac, c m le ene, and e e, l, di, claim an, liabili ha, e e f an, l,
h, e e a i, ing f m in eliance n he h le an, a f he c n en, f hi,
ann ncemen.



JOINN

JOINN LABORATORIES (CHINA) CO., LTD.

北京昭衍新藥研究中心股份有限公司

(A j in, ck c m an, inc a ed in he Pe, le, R blic f China i h limi ed liabili)

(S, q C, d : 6127)

2024 FIRST QUARTERLY REPORT

Q () 0.

C, a, G, 0. 0

0,

A, a he da e f hi, ann ncemen, he B a d c
and e ec i e Di ec, M. Z C nglin, M.
Dalin a, e ec i e Di ec, and M. S n Min
and M. Zhang Fan a, ind enden n n-e ec i

IMPORTANT NOTICE

... ..

... ..

... ..

...

I. MAJOR FINANCIAL DATA

(I) Key financial data and calculations

Item	Reported	Change Reported Period Change Period (%)
...	... 0, 00
...
...	... 0, ... ,
...	...	/
... .. (...)	... 0. , .00
... .. (...)	... 0. , .00
... (%)

	A, d R P d	A, d a a	C, a a c, a d d, a a (%)
	0	0,0	0,0
	00.		

D c acc da a d a c a d ca C a

1. Fac a c a b ab a d d c a

... ..

) 0, 00

) 0, 00
... .. 0.0 %
(... .. 0, 00),

) 00

2. C a

... .. 00.

... ..

(II) N₁- c ... a d a

✓

N ₁ - c ...	A ...	D c ...
...	... 0 ...	
...	... 0 ...	
...	... 0 ...	
...		
...		
...		
...		
...		
...		
...		
...		
...		

(III) C, a₁ acc₁ da₁ a₁ d₁ a₁ c₁ a₁ d₁ ca₁ t₁ a₁ d₁ a₁ c.

✓ □

L ₁	C, a ₁ (%)	Ma ₁ a ₁
<p>.....</p>	<p>.....</p>	
<p>.....</p>	<p>.....</p>	<p>.....</p>
<p>.....</p>	<p>.....,00</p>	<p>.....</p>
<p>.....</p>	<p>.....,00</p>	<p>.....</p>
<p>.....</p>	<p>.....</p>	<p>.....</p>
<p>.....</p>	<p>/</p>	<p>.....</p>

II. INFORMATION OF SHAREHOLDERS

(I) Shareholders holding 10% or more of the total number of shares of the Company as of the end of the reporting period

Name of Shareholder	Type of Shares	Number of Shares	Percentage (%)	Number of Shares Held by Shareholder	Shareholding Ratio	
					Shareholding Ratio (%)	Number of Shares
Shareholder A	Ordinary Shares	10,000,000	10.00	10,000,000	10.00	10,000,000
Shareholder B	Ordinary Shares	5,000,000	5.00	5,000,000	5.00	5,000,000
Shareholder C	Ordinary Shares	3,000,000	3.00	3,000,000	3.00	3,000,000
Shareholder D	Ordinary Shares	2,000,000	2.00	2,000,000	2.00	2,000,000
Shareholder E	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder F	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder G	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder H	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder I	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder J	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder K	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder L	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder M	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder N	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder O	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder P	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder Q	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder R	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder S	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder T	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder U	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder V	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder W	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder X	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder Y	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000
Shareholder Z	Ordinary Shares	1,000,000	1.00	1,000,000	1.00	1,000,000

S, a, d, 10, d, a, b, c, ad, c, ad			
Na, a, d	N b, a b, c, ad, c, ad	Ca, d, b, a	
		Ca, a, a	N b, a
	, 0,		, 0,
	, ,		, ,
	, , f		, , f
	, 0, 0,		, 0, 0,
	, , 0,		, , 0,
	, 0, f,		, 0, f,
	0, 0, ,		0, 0, ,
	0, , 0		0, , 0
	, , 0		, , 0
	, , ,		, , ,
	<p>... ..</p>		
	<p>... ..</p>		

(II) **F** **a** **c** **a** **t** **a** **t**

C **a** **d** **B** **a** **c** **S** **t**

()

I	31 Ma c, 2024	31 D e b 2023
C a t a t :		
a	r	r
a		
a		
a	,0	,0
a		
a	, 00.00	, 00.00
a	r	0,0
a		
a	00, r	0, r
a		
a		
a		
a	r	, 0,
a		
a		
a		
a	,0	,0
a		
a	0, r 0.	
a		
a	, r 0	, 0,0,
a	r 0	r
a	r	,0.

Iš	31 Ma c, 2024	31 D e s e m b e r s 2023
N u o s i t a i:		
Iš viso		
Iš viso		
Iš viso		
Iš viso		
Iš viso	1 000,000.00	1 000,000.00
Iš viso	1 000,000.00	1 000,000.00
Iš viso	1 000,000.00	1 000,000.00
Iš viso	1 000,000.00	1 000,000.00
Iš viso	1 000,000.00	1 000,000.00
Iš viso	1 000,000.00	1 000,000.00
Iš viso	1 000,000.00	1 000,000.00
Iš viso	1 000,000.00	1 000,000.00
Iš viso	1 000,000.00	1 000,000.00
Iš viso	1 000,000.00	1 000,000.00
Iš viso	1 000,000.00	1 000,000.00
Iš viso	1 000,000.00	1 000,000.00
Iš viso	1 000,000.00	1 000,000.00
Iš viso	1 000,000.00	1 000,000.00
Iš viso	1 000,000.00	1 000,000.00
Iš viso	1 000,000.00	1 000,000.00
Iš viso	1 000,000.00	1 000,000.00
Iš viso	1 000,000.00	1 000,000.00
C i n i s a b i r a m a i:		
Iš viso		
Iš viso		
Iš viso		
Iš viso		
Iš viso		
Iš viso		
Iš viso	1 000,000.00	1 000,000.00
Iš viso		
Iš viso	1 000,000.00	1 000,000.00

Lp	31 Marts, 2024	31 Desember, 2023
Ongkos Pokok (Cost of Sales):		
Penjualan (Sales)	1.000.000,00	1.000.000,00
Penjualan kembali (Sales returns)		
Penjualan rusak (Sales damaged)		
Penjualan diskon (Sales discounts)		
Penjualan tunai (Sales cash)	1.000.000,00	1.000.000,00
Penjualan kredit (Sales credit)	0,00	0,00
Penjualan tunai (Sales cash)	0,00	0,00
Penjualan kredit (Sales credit)		
Penjualan tunai (Sales cash)		
Penjualan kredit (Sales credit)		
Penjualan tunai (Sales cash)	1.000.000,00	1.000.000,00
Penjualan kredit (Sales credit)		
Penjualan tunai (Sales cash)	1.000.000,00	1.000.000,00
Penjualan kredit (Sales credit)		
Penjualan tunai (Sales cash)	1.000.000,00	1.000.000,00
Penjualan kredit (Sales credit)		
Penjualan tunai (Sales cash)	1.000.000,00	1.000.000,00
Penjualan kredit (Sales credit)		

Legal Representative:
F. Y. A.

Chief Financial Officer:
Y. A.

Director of Accounting:
Y. A.

I, II	F, M, Y a, t, 2024	F, M, Y a, t, 2023
.....	, 0, ..	, .., .. 0
..... (.....)	, .., 0 ..	, .., 0.0
.....	, .., 0..	, .., ..
.....		
..... (.....)		
..... (.....)		
..... (.....)	, 0,0 .. 0.	, .., .., 0, ..
..... (.....)	, .., ..	, 0,0, ..
..... (.....)	, .., .., .00	, .., .., 0
..... (.....)		
III. O a, t (d ca, t)	, .., .00, ..	, .., .., ..
.....	, 0, .., ..	, .., .., 0
.....	, 0, ..	, .., .., ..
IV. P a, t b (d ca, t)	, .., 0,0 ..	, .., .., ..
.....	, .., .., ..	, .., .., ..
V. N a, t (d ca, t)	, .., .., 0 .0	, .., 0,0, ..
()		
..... (.....)	, .., .., 0 .0	, .., 0,0, ..
..... (.....)		
()		
..... (.....)	, .., .., ..	, .., .., ..
..... (.....)	, .., .., ..0	, .., .., ..

I, II	F, M, J, A, S, O, N, 2024	F, M, J, A, S, O, N, 2023
VI. O'qibalar, o'ylar, haftalar, kunlar		
() I o'qibalar, o'ylar, haftalar, kunlar		
() II o'qibalar, o'ylar, haftalar, kunlar		
() III o'qibalar, o'ylar, haftalar, kunlar		
() IV o'qibalar, o'ylar, haftalar, kunlar		
() V o'qibalar, o'ylar, haftalar, kunlar		
() VI o'qibalar, o'ylar, haftalar, kunlar		
() VII o'qibalar, o'ylar, haftalar, kunlar		
() VIII o'qibalar, o'ylar, haftalar, kunlar		
() IX o'qibalar, o'ylar, haftalar, kunlar		
() X o'qibalar, o'ylar, haftalar, kunlar		
() XI o'qibalar, o'ylar, haftalar, kunlar		
() XII o'qibalar, o'ylar, haftalar, kunlar		
() XIII o'qibalar, o'ylar, haftalar, kunlar		
() XIV o'qibalar, o'ylar, haftalar, kunlar		
() XV o'qibalar, o'ylar, haftalar, kunlar		

Lü	F. 2024	F. 2023
VII. T. c.	Q.	, 0.
()	,	,
()	,	,
VIII. Ea, a :		
()	, 0.	0.
()	, 0.	0.

..... 0
 (..... 0).

Legal Representative:
 F. Y. a

Chief Financial Officer :
 Y. A. a

Director of the Accounting
 Department :
 Y. A. a

